CureVac (NASDAQ:CVAC – Get Free Report) and Immunocore (NASDAQ:IMCR – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, profitability, institutional ownership, valuation and earnings.
Analyst Ratings
This is a breakdown of current ratings and target prices for CureVac and Immunocore, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| CureVac | 1 | 0 | 0 | 0 | 1.00 |
| Immunocore | 1 | 4 | 6 | 1 | 2.58 |
Immunocore has a consensus target price of $56.38, indicating a potential upside of 91.69%. Given Immunocore’s stronger consensus rating and higher possible upside, analysts clearly believe Immunocore is more favorable than CureVac.
Earnings and Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| CureVac | $70.74 million | 14.78 | $175.50 million | $0.72 | 6.47 |
| Immunocore | $400.02 million | 3.79 | -$35.51 million | ($0.37) | -79.49 |
CureVac has higher earnings, but lower revenue than Immunocore. Immunocore is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares CureVac and Immunocore’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| CureVac | 199.92% | -23.03% | -19.09% |
| Immunocore | -4.20% | -4.54% | -1.66% |
Insider & Institutional Ownership
17.3% of CureVac shares are owned by institutional investors. Comparatively, 84.5% of Immunocore shares are owned by institutional investors. 2.1% of CureVac shares are owned by insiders. Comparatively, 10.1% of Immunocore shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Volatility and Risk
CureVac has a beta of 1.77, suggesting that its stock price is 77% more volatile than the S&P 500. Comparatively, Immunocore has a beta of 0.81, suggesting that its stock price is 19% less volatile than the S&P 500.
Summary
Immunocore beats CureVac on 9 of the 15 factors compared between the two stocks.
About CureVac
CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.
About Immunocore
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company’s product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.
Receive News & Ratings for CureVac Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CureVac and related companies with MarketBeat.com's FREE daily email newsletter.
